IT1270993B - ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS - Google Patents
ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTSInfo
- Publication number
- IT1270993B IT1270993B ITMI940506A ITMI940506A IT1270993B IT 1270993 B IT1270993 B IT 1270993B IT MI940506 A ITMI940506 A IT MI940506A IT MI940506 A ITMI940506 A IT MI940506A IT 1270993 B IT1270993 B IT 1270993B
- Authority
- IT
- Italy
- Prior art keywords
- derivatives
- quinzolylaminic
- antagonists
- alpha
- active
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Vengono descritti nuovi derivati chinazolilaminici efficaci nel bloccare i recettori ?1-adrenergici. Questi composti possono essere utilizzati quali utili agenti terapeutici per il trattamento delle malattie ed affezioni implicanti un'iperattività del sistema ?-adrenergico quali, ad esempio, l'ipertensione arteriosa e l'iperplasia prostatica benigna (BPH). Vengono inoltre descritti i metodi di preparazione di tali composti.New quinazolylamin derivatives are described that are effective in blocking? 1-adrenergic receptors. These compounds can be used as useful therapeutic agents for the treatment of diseases and diseases involving hyperactivity of the? -Adrenergic system such as, for example, arterial hypertension and benign prostatic hyperplasia (BPH). The methods of preparing these compounds are also described.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI940506A IT1270993B (en) | 1994-03-18 | 1994-03-18 | ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS |
IL11302495A IL113024A (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having alpha-antagonist activity their preparation and pharmaceutical compositions comprising them |
AT95911342T ATE201400T1 (en) | 1994-03-18 | 1995-03-17 | CHINAZOLINYLAMINO DERIVATIVES WITH ALFA ANTAGONIST EFFECT |
PCT/EP1995/001001 WO1995025726A1 (en) | 1994-03-18 | 1995-03-17 | QUINAZOLINYL-AMINO DERIVATIVES HAVING α-ANTAGONIST ACTIVITY |
DE69521037T DE69521037T2 (en) | 1994-03-18 | 1995-03-17 | CHINAZOLINYLAMINO DERIVATIVES WITH ALFA ANTAGONIST EFFECT |
AU18948/95A AU1894895A (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having alpha-antagonist activity |
ZA952208A ZA952208B (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having alpha-antagonist activity |
PT95911342T PT750614E (en) | 1994-03-18 | 1995-03-17 | AMINO-KINAZOLINYL DERIVATIVES WHICH HAVE ALPHA ANTAGONIST ACTIVITY |
ES95911342T ES2158938T3 (en) | 1994-03-18 | 1995-03-17 | AMINOQUINAZOLINE DERIVATIVES THAT HAVE ALFA-ANTAGONIST ACTIVITY. |
DK95911342T DK0750614T3 (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl amino derivatives with alpha antagonist activity |
US08/716,160 US5798362A (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having α-antagonist activity |
EP95911342A EP0750614B1 (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having alpha-antagonist activity |
SI9530495T SI0750614T1 (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having alpha-antagonist activity |
JP52437095A JP3683911B2 (en) | 1994-03-18 | 1995-03-17 | Quinazolinyl-amino derivatives having α-antagonistic activity |
TW084105132A TW416951B (en) | 1994-03-18 | 1995-05-23 | Quinazolinyl-amino derivatives having <alpha>-antagonist activity |
GR20010401292T GR3036443T3 (en) | 1994-03-18 | 2001-08-23 | Quinazolinyl-amino derivatives having alpha-antagonist activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI940506A IT1270993B (en) | 1994-03-18 | 1994-03-18 | ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS |
Publications (3)
Publication Number | Publication Date |
---|---|
ITMI940506A0 ITMI940506A0 (en) | 1994-03-18 |
ITMI940506A1 ITMI940506A1 (en) | 1995-09-18 |
IT1270993B true IT1270993B (en) | 1997-05-26 |
Family
ID=11368249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ITMI940506A IT1270993B (en) | 1994-03-18 | 1994-03-18 | ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS |
Country Status (15)
Country | Link |
---|---|
US (1) | US5798362A (en) |
EP (1) | EP0750614B1 (en) |
JP (1) | JP3683911B2 (en) |
AT (1) | ATE201400T1 (en) |
AU (1) | AU1894895A (en) |
DE (1) | DE69521037T2 (en) |
DK (1) | DK0750614T3 (en) |
ES (1) | ES2158938T3 (en) |
GR (1) | GR3036443T3 (en) |
IL (1) | IL113024A (en) |
IT (1) | IT1270993B (en) |
PT (1) | PT750614E (en) |
TW (1) | TW416951B (en) |
WO (1) | WO1995025726A1 (en) |
ZA (1) | ZA952208B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747490A (en) * | 1995-09-29 | 1998-05-05 | Merck & Co., Inc. | Alpha 1b adrenergic receptor antagonists |
AU7692896A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
IT1286302B1 (en) * | 1996-04-10 | 1998-07-08 | Rotta Research Lab | CHINAZOLINE-4-AMINO-2- (PIPERIDINO-1-IL-4-SUBSTITUTED) WITH ANTI-HYPERTENSIVE ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND USE |
GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9711650D0 (en) * | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
US7186726B2 (en) * | 1998-06-30 | 2007-03-06 | Neuromed Pharmaceuticals Ltd. | Preferentially substituted calcium channel blockers |
US6355641B1 (en) | 1999-03-17 | 2002-03-12 | Syntex (U.S.A.) Llc | Oxazolone derivatives and uses thereof |
IT1312310B1 (en) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION |
ITMI20012060A1 (en) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | NEW N-ACYLATED HETEROCYCLES |
US20040058962A1 (en) * | 2002-06-14 | 2004-03-25 | Amedeo Leonardi | Phenylalkylamines and pyridylalkylamines |
US7071197B2 (en) | 2002-06-14 | 2006-07-04 | Recordati S.A. | N,N-disubstituted diazocycloalkanes |
US20040072839A1 (en) * | 2002-06-14 | 2004-04-15 | Amedeo Leonardi | 1-Phenylalkylpiperazines |
CA2550012A1 (en) * | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
US20060264442A1 (en) * | 2005-05-18 | 2006-11-23 | Allergan, Inc. | Methods for the treatment of ocular and neurodegenerative conditions in a mammal |
CA2877526A1 (en) | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE925468C (en) * | 1941-08-13 | 1955-03-21 | Hoechst Ag | Process for the preparation of ª †, ª † -Diaryl-propyl-amines |
GB679676A (en) * | 1950-04-03 | 1952-09-24 | Dow Chemical Co | Improved method for the production of salts of aromatic-oxy-aliphatic carboxylic acids |
US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
US3635979A (en) * | 1969-09-29 | 1972-01-18 | Pfizer | Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines |
DE2143730A1 (en) * | 1971-09-01 | 1973-03-08 | Byk Gulden Lomberg Chem Fab | Substd pyridines prepn - hypotensives, analgesics and inters |
US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
US4062844A (en) * | 1976-09-20 | 1977-12-13 | Pfizer Inc. | Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines |
FR2389614A1 (en) * | 1977-05-05 | 1978-12-01 | Synthelabo | Antihypertensive 2,4-di:amino-quinazoline(s) - prepd. from a 2-halo-4-amino-quinazoline and a secondary amine |
US4607034A (en) * | 1979-10-29 | 1986-08-19 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | Quinazoline derivatives and pharmaceutical composition thereof |
US4426382A (en) * | 1980-02-13 | 1984-01-17 | Sankyo Company Limited | 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use |
CS236097B1 (en) * | 1983-06-01 | 1985-05-15 | Jan Koenig | Acylderivatives of 2-piperazinochinazoline and method of their preparation |
AT384218B (en) * | 1985-12-04 | 1987-10-12 | Gerot Pharmazeutika | METHOD FOR PRODUCING NEW CHINAZOLINE DERIVATIVES |
US5110927A (en) * | 1987-12-31 | 1992-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Prazosin analog with increased selectivity and duration of action |
-
1994
- 1994-03-18 IT ITMI940506A patent/IT1270993B/en active IP Right Grant
-
1995
- 1995-03-17 WO PCT/EP1995/001001 patent/WO1995025726A1/en active IP Right Grant
- 1995-03-17 ZA ZA952208A patent/ZA952208B/en unknown
- 1995-03-17 DK DK95911342T patent/DK0750614T3/en active
- 1995-03-17 IL IL11302495A patent/IL113024A/en not_active IP Right Cessation
- 1995-03-17 US US08/716,160 patent/US5798362A/en not_active Expired - Fee Related
- 1995-03-17 JP JP52437095A patent/JP3683911B2/en not_active Expired - Fee Related
- 1995-03-17 AU AU18948/95A patent/AU1894895A/en not_active Abandoned
- 1995-03-17 EP EP95911342A patent/EP0750614B1/en not_active Expired - Lifetime
- 1995-03-17 DE DE69521037T patent/DE69521037T2/en not_active Expired - Fee Related
- 1995-03-17 AT AT95911342T patent/ATE201400T1/en not_active IP Right Cessation
- 1995-03-17 ES ES95911342T patent/ES2158938T3/en not_active Expired - Lifetime
- 1995-03-17 PT PT95911342T patent/PT750614E/en unknown
- 1995-05-23 TW TW084105132A patent/TW416951B/en not_active IP Right Cessation
-
2001
- 2001-08-23 GR GR20010401292T patent/GR3036443T3/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ITMI940506A1 (en) | 1995-09-18 |
IL113024A0 (en) | 1995-06-29 |
AU1894895A (en) | 1995-10-09 |
ZA952208B (en) | 1995-12-28 |
IL113024A (en) | 2000-07-26 |
JPH09511238A (en) | 1997-11-11 |
ATE201400T1 (en) | 2001-06-15 |
EP0750614A1 (en) | 1997-01-02 |
GR3036443T3 (en) | 2001-11-30 |
TW416951B (en) | 2001-01-01 |
JP3683911B2 (en) | 2005-08-17 |
WO1995025726A1 (en) | 1995-09-28 |
EP0750614B1 (en) | 2001-05-23 |
DE69521037T2 (en) | 2001-10-25 |
ITMI940506A0 (en) | 1994-03-18 |
DK0750614T3 (en) | 2001-09-10 |
PT750614E (en) | 2001-10-31 |
ES2158938T3 (en) | 2001-09-16 |
US5798362A (en) | 1998-08-25 |
DE69521037D1 (en) | 2001-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IT1270993B (en) | ACTIVE QUINZOLYLAMINIC DERIVATIVES AS ALPHA-ANTAGONISTS | |
EA200000220A1 (en) | COMBINATION OF TYROSINKINASE INHIBITOR AND CHEMICAL STERILIZATION FOR TREATMENT OF PROSTATE GLAND | |
ATE233738T1 (en) | SMALL MOLECULES APPLICABLE IN THE TREATMENT OF INFLAMMATORY DISEASES | |
DK1039912T3 (en) | Angiostatic agents and preparations for the treatment of GLC1A glaucoma | |
TR200002773T2 (en) | Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's. | |
DK0689426T3 (en) | Therapeutic agent for the treatment of melanomas | |
DK0943328T3 (en) | Combination therapy for prophylaxis and / or treatment of benign prostatic hyperplasia | |
IS4972A (en) | Use of the chelating agent clioquinol in the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease | |
DE69710065T2 (en) | Androstene DERIVATIVES | |
MY128558A (en) | Antipsoriatic nail polish | |
ES2051733T3 (en) | PROCEDURE FOR OBTAINING A TAMOXIFEN BASED MEDICINE FOR LOCAL USE. | |
DE59705562D1 (en) | 7ALPHA- (5-METHYLAMINOPENTYL) -ESTRATRIENE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 7ALPHA- (5-METHYLAMINOPENTYL) -ESTRATRIENE AND THE USE THEREOF FOR USE THEREOF | |
TR200002248T2 (en) | New dihydroxyhexanoic acid derivatives | |
ATE139226T1 (en) | AMINOSULFONYL UREA ACAT INHIBITORS | |
MY118986A (en) | Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
IT1290781B1 (en) | ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES. | |
BG101126A (en) | The use of muramylpeptide compounds | |
ATE106732T1 (en) | MEDICATION PREPARATION CONTAINING STIGMASTA-4-EN-3-ONE AND USE THEREOF. | |
BR9203266A (en) | COMPOUND, PHARMACEUTICAL FORMULATION, PROCESS TO INHIBIT 5ALFA-REDUCTASE, PROCESSES TO TREAT BENIGN PROSTATE HYPERPLASIA, SEBORRHEA AND ANDROGENIC ALOPECIA | |
FR2718965B1 (en) | New therapeutic application of spiramycin. | |
BR0015424A (en) | Analogs of hydroxyeicosatetraenoic acid and methods of its use in the treatment of dry eye disorders | |
ITMI920850A0 (en) | BENZOFURAN-IMIDAZOLES FOR USE AS AROMATISIA INHIBITORS 17,20-LIASINELLA RPOPHYLAXIS AND TREATMENT OF BREAST CANCER AND BENIGN PROSTATIC HYPERPLASIA | |
MX9800697A (en) | Use of calendula glycosides for the treatment of psoriasis. | |
UA9522A (en) | Method for treating autoimmune thyroiditis | |
UA8280A (en) | Method for treating psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
0001 | Granted | ||
TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19970327 |